-- 在週三下午交易中，波士頓科學公司 (BSX) 股價下跌 3.4%，此前大和證券將該股評級從“跑贏大盤”下調至“中性”，並將目標股價從之前的每股 83 美元下調至 60 美元。 成交量約 1,290 萬股，而日均成交量超過 1,760 萬股。
Price: $56.49, Change: $-1.96, Percent Change: -3.35%
Related Articles
Mining & Metals
Primaris REIT Reports Higher Profit, Total Rental Revenue for First Quarter; Full-year Outlook Maintained
Primaris Real Estate Investment Trust (PMZ-UN.TO) after trade Wednesday reported higher total rental revenue and profit for the first quarter and reaffirmed its 2026 outlook.The REIT earned $41.9 million, or $0.305 per unit, in the period, up from $31.2 million, or $0.257, a year ago. Corresponding FactSet figures were not available.Total rental revenue rose to $177.04 million from $150.2 million a year prior. FactSet expected sales of $180.8 million.Among other highlights, Primaris cited funds from operations per average diluted unit of $0.425 compared with $0.439 a year ago. FactSet projected FFO per share of $0.44."Our low leverage, low payout ratio model is a critical pillar to our strategy. We have significant liquidity with the full availability on our unsecured credit facility with no debt maturing in 2026, Chief Financial Officer Rags Davloor said."With strong liquidity, very low leverage, and a low payout ratio, we are well positioned to fund internal growth, enhance portfolio quality, and create long term value for our unitholders," Chief Executive Alex Avery added.The REIT said it is maintaining its full-year 2026 guidance.The REIT's units closed down $0.05 to $18.98 on the Toronto Stock Exchange.
$PMZ-UN.TO
Insider Trading
Maplight Therapeutics Insider Sold Shares Worth $1,347,066, According to a Recent SEC Filing
Anatol Kreitzer, Chief Discovery Officer, on April 27, 2026, sold 45,422 shares in Maplight Therapeutics (MPLT) for $1,347,066. Following the Form 4 filing with the SEC, Kreitzer has control over a total of 211,190 voting common shares of the company, with 211,190 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000202123826000008/xslF345X05/form4-04292026_040429.xml
$MPLT
Insider Trading
Maplight Therapeutics Insider Sold Shares Worth $2,087,687, According to a Recent SEC Filing
Jonathan Gillis, Chief Administrative and Accounting Officer and Principal Accounting Officer, on April 27, 2026, sold 69,835 shares in Maplight Therapeutics (MPLT) for $2,087,687. Following the Form 4 filing with the SEC, Gillis has control over a total of 181,219 voting common shares of the company, with 181,219 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000170995426000008/xslF345X05/form4-04292026_040431.xml
$MPLT